Cas:1218-69-5 2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one manufacturer & supplier

Chemical Name:2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one

CAS.NO:1218-69-5

Synonyms:2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one;2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one;4H-1,3-Benzoxazin-4-one, 2-(2-hydroxyphenyl)-

Molecular Formula:C₁₄H₉NO₃

Molecular Weight:239.226

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:425.0±47.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.657

PSA:63.33000

Exact Mass:239.058243

LogP:2.06

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4H-1,3-Benzoxazin-4-one, 2-(2-hydroxyphenyl)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4H-1,3-Benzoxazin-4-one, 2-(2-hydroxyphenyl)- Use and application,2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one technical grade,usp/ep/jp grade.

Related News: Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. 2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one manufacturer Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. 2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one supplier The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2-(2-Hydroxyphenyl)-4H-1,3-benzoxazin-4-one factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.